γ-secretase inhibition has been shown to increase BCMA expression in MM cells and reduce sBCMA in vitro. Recent studies have shown that the ubiquitin proteasome system degrades BCMA and that treatment with a proteasome inhibitor increases BCMA surface expression and improves BCMA CAR-T efficacy, justifying the combination of PI and BCMA-CAR-T in future studies (115). Here, TNFRSF17 is linked to Miyoshi myopathy.